Panel Discussion – Decision uncertainty in HTA: what next after managed access?

Outcomes-based payment models (OBPs) offer the opportunity to minimize the uncertainty associated with the reimbursement of new therapies, particularly those that are more innovative. However, the design and implementation of OBPs is difficult because they require a whole system shift, from how data is collected at the point of care, to how it translates into a funding decision. The aim of this panel discussion is to understand multi-stakeholder perspectives on the the requirements and considerations needed to bring forth an OBP. This video is funded by Pfizer and is intended for the general public.